NDSI
BRTX icon

Newman Dignan & Sheerar Inc’s BioRestorative Therapies BRTX Stock Holding History

Newman Dignan & Sheerar Inc’s Portfolio BRTX Stock Details BRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,522
Closed -$19.2K – 182
2025
Q2 		$19.2K Hold
11,522
– – ﹤0.01% 191
2025
Q1 		$20.5K Hold
11,522
– – 0.01% 171
2024
Q4 		$16.5K Buy
11,522
+1,000
+10% +$1.55K ﹤0.01% 179
2024
Q3 		$16.6K Buy
+10,522
New +$17.3K ﹤0.01% 187

Other funds holding BRTX

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.2B AUM 26.51% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Newman Dignan & Sheerar Inc's BRTX Position: Q3 2025 in Review

Newman Dignan & Sheerar Inc sold out of BioRestorative Therapies (BRTX) in Q3 2025, closing a stake of 11,522 shares — an estimated $19.2K sold.

Newman Dignan & Sheerar Inc first reported a position in BRTX in Q3 2024 and held it in 4 quarters. The position peaked at $20.5K in Q1 2025. 14 funds tracked by Wall St. Rank hold BRTX as of Q3 2025.

  • Newman Dignan & Sheerar Inc reported no remaining BioRestorative Therapies position as of Q3 2025 after selling out during the quarter.
  • Newman Dignan & Sheerar Inc sold 11,522 BioRestorative Therapies shares in Q3 2025, an estimated $19.2K.
  • Newman Dignan & Sheerar Inc first reported a position in BioRestorative Therapies in Q3 2024 and held it in 4 quarters.
  • Newman Dignan & Sheerar Inc's BioRestorative Therapies position peaked at $20.5K in Q1 2025.
  • 14 funds tracked by Wall St. Rank held BioRestorative Therapies as of Q3 2025.

Based on Newman Dignan & Sheerar Inc's 13F filing for Q3 2025, filed 9 Oct 2025.